“HepaRegeniX develops a unique, therapeutic concept for the treatment of acute and chronic liver diseases. It is based on unlocking the regenerative capacity of liver cells, even in severely diseased livers.”
Dr. Michael Lutz
CEO
Dr. Michael Lutz
CEO
Location: Germany, Baden-Württemberg, Ulm
Total raised: $53.1M
Investors 1
| Date | Name | Website |
| - | Coparion | coparion.v... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.04.2025 | - | $24.32M | - |
| 10.07.2024 | Series C | $16.25M | - |
| 24.01.2020 | Series B | $12.53M | - |
Mentions in press and media 13
| Date | Title | Description |
| 16.04.2025 | HepaRegeniX Secures €21.5 Million to Propel Liver Regeneration Research | In the heart of Tuebingen, Germany, HepaRegeniX GmbH is making waves in the medical world. The clinical-stage company has successfully closed a €21.5 million financing round, a significant boost for its innovative approach to treating liver... |
| 15.04.2025 | HepaRegeniX Closes €21.5M in Funding | HepaRegeniX GmbH, a Tuebingen, Germany-based clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, raised €21.5M in funding. Backers included Wellington Partners. The company intends to use the funds to... |
| 15.04.2025 | HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration | Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financ... |
| 13.07.2024 | HepaRegeniX: Revolutionizing Liver Regeneration with Innovative Therapy | In a groundbreaking development, HepaRegeniX, a clinical stage company based in Tuebingen, Germany, has successfully secured €15 million in Series C funding to propel the clinical development of HRX-215, a novel regenerative therapy aimed a... |
| 10.07.2024 | HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration | Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniXDr. Linda Greenbaum joins H... |
| 10.07.2024 | HepaRegeniX Raises €15M in Series C Funding | HepaRegeniX, a Tuebingen, Germany-based clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, raised €15M in Series C funding. The round was led by Vesalius Biocapital IV with ... |
| 30.03.2022 | HepaRegeniX Appoints Elias Papatheodorou as New Chairman of the Board of Directors | TUBINGEN, GERMANY / ACCESSWIRE / March 30, 2022 / HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Elias Pa... |
| 04.11.2021 | HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences | DGAP-News: HepaRegeniX GmbH / Key word(s): Conference/Alliance HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences 04.11.2021 / 09:00 The issuer is solely responsible for t... |
| 20.10.2021 | HepaRegeniX GmbH : initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther | DGAP-News: HepaRegeniX GmbH / Key word(s): Alliance HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther 20.10... |
| 24.01.2020 | HepaRegeniX Closes Over €11M Series B Financing round | HepaRegeniX, a Tübingen, Germany-based preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases, closed an over €11M Series B financing round. Backers included Boehringer Ingelheim Venture F... |
Show more